Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis
| Autor: | Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | HIV Research & Clinical Practice, Vol 22, Iss 2, Pp 55-61 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2578-7470 25787489 |
| DOI: | 10.1080/25787489.2021.1915652 |
| Popis: | Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety among patients with acute or early HIV-1 infection who rapidly initiate treatment. Methods: DIAMOND (ClinicalTrials.gov Identifier: NCT03227861), a phase 3 study, evaluated the efficacy/safety of D/C/F/TAF 800/150/200/10 mg in rapid initiation. Adults aged ≥18 years began D/C/F/TAF within 14 days of diagnosis, prior to the availability of screening/baseline laboratory results. In this subgroup analysis, virologic response (HIV-1 RNA |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|